OncoMatch/Clinical Trials/NCT03649880
Feasibility of FMISO in Brain Tumors
Official title: Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors
Is NCT03649880 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including ¹⁸F-Fluoromisonidazole and Ferumoxytol for idh wild type glioblastoma.
Treatment: ¹⁸F-Fluoromisonidazole · Ferumoxytol · Gadolinium — This phase II trial studies how well 18F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. Two contrast agents called gadolinium and ferumoxytol are used during some of the MRI scans. A contrast agent is a liquid-like dye that is given intravenously (IV) to help imaging machines create pictures. The study drug, called FMISO, provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Lab requirements
Blood counts
Adequate organ function as demonstrated by a chart review of platelets, renal, hepatic, and coagulation.
Kidney function
Department of Diagnostic Radiology clinical policy for assessing renal function prior to injecting gadolinium-based contrast. If there is a history of poor kidney function, a point of care serum creatinine test may be performed to ensure adequate kidney function prior to FMISO administration.
Liver function
Adequate organ function as demonstrated by a chart review of platelets, renal, hepatic, and coagulation.
Adequate organ function as demonstrated by a chart review of platelets, renal, hepatic, and coagulation. ... If there is a history of poor kidney function, a point of care serum creatinine test may be performed to ensure adequate kidney function prior to FMISO administration. If there is a history of any other poor organ function, we will not administer Ferumoxytol, but the subject may receive all other study interventions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- OHSU Knight Cancer Institute · Portland, Oregon
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03649880 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages